Art. -Nr.: HY-101462

Copy Link Print Information

RAD51 Inhibitor B02

(Synonyms: B02)

15 Cited Publications

Kundenbewertung

Based on 15 publication(s) in Google Scholar

RAD51 Inhibitor B02 (B02) is an inhibitor of human RAD51 with an IC₅₀ of 27.4 μM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.89%
CAS. Nr.: 1290541-46-6
Formel: C₂₂H₁₇N₃O
Molecular Weight:339.39

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

RAD51 Inhibitor B02 Chemical Structure

CAS. Nr.: 1290541-46-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (15)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

RAD51 Inhibitor B02 (B02) is an inhibitor of human RAD51 with an IC₅₀ of 27.4 μM.

IC₅₀ & Target

IC50: 27.4 μM (hRAD51)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
BT-549	IC₅₀	35.4 μM Compound: 9; B02	Cytotoxicity against human BT549 cells assessed as decrease in cell viability after 120 hrs by MTS assay Cytotoxicity against human BT549 cells assessed as decrease in cell viability after 120 hrs by MTS assay	[PMID: 28545975]
HCC1937	IC₅₀	89.1 μM Compound: 9; B02	Cytotoxicity against human HCC1937 cells assessed as decrease in cell viability after 120 hrs by MTS assay Cytotoxicity against human HCC1937 cells assessed as decrease in cell viability after 120 hrs by MTS assay	[PMID: 28545975]
Hs-578T	IC₅₀	9.6 μM Compound: 9; B02	Cytotoxicity against human Hs578T cells assessed as decrease in cell viability after 120 hrs by MTS assay Cytotoxicity against human Hs578T cells assessed as decrease in cell viability after 120 hrs by MTS assay	[PMID: 28545975]
MCF-10A	IC₅₀	47.7 μM Compound: 9; B02	Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 120 hrs by MTS assay Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 120 hrs by MTS assay	[PMID: 28545975]
MDA-MB-231	IC₅₀	11.1 μM Compound: 9; B02	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 120 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 120 hrs by MTS assay	[PMID: 28545975]
MDA-MB-436	IC₅₀	5.7 μM Compound: 9; B02	Cytotoxicity against human MDA-MB-436 cells assessed as decrease in cell viability after 120 hrs by MTS assay Cytotoxicity against human MDA-MB-436 cells assessed as decrease in cell viability after 120 hrs by MTS assay	[PMID: 28545975]
MDA-MB-468	IC₅₀	10.2 μM Compound: 9; B02	Cytotoxicity against human MDA-MB-468 cells assessed as decrease in cell viability after 120 hrs by MTS assay Cytotoxicity against human MDA-MB-468 cells assessed as decrease in cell viability after 120 hrs by MTS assay	[PMID: 28545975]
SUM-159-PT	IC₅₀	84.1 μM Compound: 9; B02	Cytotoxicity against human SUM159PT cells assessed as decrease in cell viability after 120 hrs by MTS assay Cytotoxicity against human SUM159PT cells assessed as decrease in cell viability after 120 hrs by MTS assay	[PMID: 28545975]

In Vitro

RAD51 Inhibitor B02 specifically inhibits human RAD51 (IC₅₀=27.4 μM), but not its E. coli homologue RecA (IC₅₀>250 μM)^[1]. The combination of B02 with cisplatin has the strongest killing effect on the human breast cancer cells MDA-MB-231^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

B02 significantly enhances the therapeutic effect of cisplatin on tumor cells in vivo. B02 is tolerated by mice at doses up to 50 mg/kg without obvious body weight loss. No inhibition of tumor growth is observed on mice solely treated by B02. Mice treated with 4 mg/kg cisplatin, however, shows a 33% inhibition of tumor growth. Finally, mice treated with 50 mg/kg B02 and 4 mg/kg cisplatin shows a 66% inhibition of tumor growth^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1290541-46-6
Appearance Solid
Molecular Weight 339.39
Formel C₂₂H₁₇N₃O
Color Light yellow to yellow
SMILES

O=C1N(CC2=CC=CC=C2)C(/C=C/C3=CC=CN=C3)=NC4=C1C=CC=C4
Synonyms

B02
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (15)

All Cell Proliferation/Viability AssayIFWB

Sort by:

Journal Impact Factor

Cell

Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors. [Abstract]

2025 Jun 26;188(13):3405-3421.e27. PMID: 40300601
Drug Resist Updat

Centromere protein U mediates the ubiquitination and degradation of RPS3 to facilitate temozolomide resistance in glioblastoma. [Abstract]

2025 May:80:101214. PMID: 40023134
Nat Commun

A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer. [Abstract]

2025 Jan 27;16(1):1077. PMID: 39870664

RAD51 Inhibitor B02 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 27;16(1):1077. [Abstract]

Response of lung and breast cell line models to DNA-PK inhibition (NU7441) and RAD51 (RAD51 Inhibitor B02 (B02, 0-100 μM, 72 h)) inhibition. Cells were irradiated with 2 Gy and treated with each small-molecule for 72h. Cell viability relative to DMSO control was assessed in a CellTiterGlo luminescence assay.
Cancer Lett

N6-methyadenosine modified SUV39H2 regulates homologous recombination through epigenetic repression of DUSP6 in gastric cancer. [Abstract]

2023 Apr 1:558:216092. PMID: 36806557
Cancer Lett

Inhibition of the DSB repair protein RAD51 potentiates the cytotoxic efficacy of doxorubicin via promoting apoptosis-related death pathways. [Abstract]

2021 Nov 1:520:361-373. PMID: 34389435
Oncogene

LncRNA CACClnc promotes chemoresistance of colorectal cancer by modulating alternative splicing of RAD51. [Abstract]

2023 Apr;42(17):1374-1391. PMID: 36906654

RAD51 Inhibitor B02 purchased from MedChemExpress. Usage Cited in: Oncogene. 2023 Apr;42(17):1374-1391. [Abstract]

RAD51 Inhibitor B02 (2 μM; 48 h) increases sensitivity of HT29 cells to Oxaliplatin or 5-FU.
Cancers (Basel)

CD81 Enhances Radioresistance of Glioblastoma by Promoting Nuclear Translocation of Rad51. [Abstract]

2021 Apr 21;13(9):1998. PMID: 33919192

RAD51 Inhibitor B02 purchased from MedChemExpress. Usage Cited in: Cancers (Basel). 2021 Apr 21;13(9):1998. [Abstract]

U251R and T98G Cells were treated with RAD51 Inhibitor B02 (B02, 10 μM), its control (1‰ DMSO), or B02 + siCD81 and then irradiated with X-rays. Representative immunostaining images (left) and quantification (right) of nuclear Rad51 foci in the cells at 2 h after 6 Gy irradiation. Blue, DAPI stained nuclear. Red, Rad51 foci.

RAD51 Inhibitor B02 purchased from MedChemExpress. Usage Cited in: Cancers (Basel). 2021 Apr 21;13(9):1998. [Abstract]

U251R and T98G Cells were treated with RAD51 Inhibitor B02 (B02, 10 μM), its control (1‰ DMSO), or B02 + siCD81 and then irradiated with X-rays. Western blot assay (left) and quantitation (right) of cytoplasmic (cyto) and nuclear (nuc) proteins of Rad51 level and CD81 at 2 h after 6 Gy irradiation.

RAD51 Inhibitor B02 purchased from MedChemExpress. Usage Cited in: Cancers (Basel). 2021 Apr 21;13(9):1998. [Abstract]

U251R and T98G Cells were treated with RAD51 Inhibitor B02 (B02, 10 μM), its control (1‰ DMSO), or B02 + siCD81 and then irradiated with X-rays. Representative immunostaining images (left) and quantification (right) of γ-H2AX foci in the cells at 2 h after 6 Gy irradiation. Blue, DAPI stained nuclear. Red, γ-H2AX foci.

RAD51 Inhibitor B02 purchased from MedChemExpress. Usage Cited in: Cancers (Basel). 2021 Apr 21;13(9):1998. [Abstract]

U251R and T98G Cells were treated with B02 (10 μM), its control (1‰ DMSO), or B02 + siCD81 and then irradiated with X-rays. Clonogenic survivals of X-ray irradiated U251R and T98G cells under different treatment of B02 or B02 + siCD81.
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Cell Signal

Gastric cancer derived mesenchymal stem cells promoted DNA repair and cisplatin resistance through up-regulating PD-L1/Rad51 in gastric cancer. [Abstract]

2023 Jun:106:110639. PMID: 36842523
Discov Oncol

RAD51 modulates in nasopharyngeal carcinoma cells by regulating Caspase-8-mediated pyroptosis. [Abstract]

2025 Jul 12;16(1):1320. PMID: 40650821
J Cancer Res Ther

Berberine enhances the radiosensitivity of osteosarcoma by targeting Rad51 and epithelial-mesenchymal transition. [Abstract]

2020;16(2):215-221. PMID: 32474504
bioRxiv

Prime assembly with linear DNA donors enables large genomic insertions. [Abstract]

2025 Jun 17:2025.06.16.659978. PMID: 40667017
Northwestern University

2024.
bioRxiv

2023 Dec 19.
Res Sq

Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cells. [Abstract]

2023 Apr 6:rs.3.rs-2688694. PMID: 37066268

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 37 mg/mL (109.02 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9465 mL

14.7323 mL

29.4646 mL

5 mM

0.5893 mL

2.9465 mL

5.8929 mL

10 mM

0.2946 mL

1.4732 mL

2.9465 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 20% DMSO 20% Cremophor EL 60% Saline

Solubility: 10 mg/mL (29.46 mM); Clear solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2 mg/mL (5.89 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2 mg/mL (5.89 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[2]

The cells are exposed for 1 h, then the cells are ished by PBS three times and refreshed by the media containing B02 (5 µM). After 7-10 days, cells are fixed and stained with staining solution (0.05% crystal violet, 50% methanol in PBS); finally cell colonies are counted^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice: Cisplatin and B02 are dissolved in NS and cremophor/DMSO/NS (1:1:3) vehicle, respectively, immediately before injection. In a combination treatment group, the mice are injected with B02 (50 mg/kg or indicated otherwise) and cisplatin (4 mg/kg or indicated otherwise). In B02 group, mice are injected with B02 and NS; in cisplatin group, mice are injected with cisplatin and B02 vehicle. Cisplatin (or NS) is administrated 3 h after B02 (or its vehicle) injection. All the treatments are executed through I.P. injections on day 11, 13, 15 and 17 after tumor cells inoculations^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Huang F, et al. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol. 2011 Jun 17;6(6):628-35. [Content Brief]

[2]. Huang F, et al. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts. PLoS One. 2014 Jun 27;9(6):e100993. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9465 mL	14.7323 mL	29.4646 mL	73.6616 mL
	5 mM	0.5893 mL	2.9465 mL	5.8929 mL	14.7323 mL
	10 mM	0.2946 mL	1.4732 mL	2.9465 mL	7.3662 mL
	15 mM	0.1964 mL	0.9822 mL	1.9643 mL	4.9108 mL
	20 mM	0.1473 mL	0.7366 mL	1.4732 mL	3.6831 mL
	25 mM	0.1179 mL	0.5893 mL	1.1786 mL	2.9465 mL
	30 mM	0.0982 mL	0.4911 mL	0.9822 mL	2.4554 mL
	40 mM	0.0737 mL	0.3683 mL	0.7366 mL	1.8415 mL
	50 mM	0.0589 mL	0.2946 mL	0.5893 mL	1.4732 mL
	60 mM	0.0491 mL	0.2455 mL	0.4911 mL	1.2277 mL
	80 mM	0.0368 mL	0.1842 mL	0.3683 mL	0.9208 mL
	100 mM	0.0295 mL	0.1473 mL	0.2946 mL	0.7366 mL

Keywords

RAD51 Inhibitor B02

15 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

RAD51 Inhibitor B02

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Anti-Breast Cancer Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Cell Death Library

Bioactive Compound Library Max

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) RAD51 Inhibitor B02

Biologische Aktivität

Chemical Information

Publications (15)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

RAD51 Inhibitor B02

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Anti-Breast Cancer Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Cell Death Library

Bioactive Compound Library Max

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) RAD51 Inhibitor B02

Biologische Aktivität

Chemical Information

Publications (15)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

RAD51 Inhibitor B02 Related Classifications

HY-101462 Related Classifications